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The numerous controlled clinical trials performed recently in pulmonary arterial hypertension
(PAH) can allow us to abandon a clinical-based treatment strategy and adopt an evidence-
based therapy. Both uncontrolled and controlled clinical trials with different compounds and
procedures are reviewed and compared in order to define the efficacy-to-side-effect ratio of
each treatment. A grading system for the level of evidence of treatments based on the number
of favorable controlled clinical trials performed with a given compound is adopted; a
treatment algorithm based on the evidence derived by clinical trials is proposed. It includes
drugs approved by regulatory agencies for the treatment of patients with PAH and/or drugs
available on the market for other indications. The algorithm is restricted to patients in New
York Heart Association (NYHA) functional class III or IV because they represent the largest
population included in controlled clinical trials. In addition, the different treatments have
been evaluated mainly in sporadic, idiopathic PAH and in PAH associated with scleroderma
or to anorexigen use. Extrapolation of these recommendations to the other PAH subgroups
should be done with caution. Oral anticoagulation is proposed for all patients, whereas
diuretic treatment and supplemental oxygen are indicated in cases of fluid retention and
hypoxemia, respectively. High doses of calcium channel blockers are indicated only in the
minority of patients who are responders to acute vasoreactivity testing. Nonresponders to
acute vasoreactivity testing, or responders who remain in NYHA functional class III, should
be considered candidates for treatment with either an endothelin receptor antagonist or a
prostanoid. Continuous intravenous administration of epoprostenol is proposed as rescue
treatment in NYHA functional class IV patients. Phosphodiesterase-V inhibitors should be
considered in patients who have failed or are not candidates to other therapies. Combination
therapy can be attempted in selected cases. Both balloon atrial septostomy and lung
transplantation are indicated for refractory patients or where medical treatment is
unavailable. (J Am Coll Cardiol 2004;43:81S–88S) © 2004 by the American College of
Cardiology Foundationu
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areatment of pulmonary arterial hypertension (PAH) has
hown a dramatic change from the slow progress in the past
ecades to the remarkable number of randomized controlled
rials (RCTs) accomplished in the past few years.
Initially, up to the 1980s, attempts to reduce pulmonary
rterial pressure were performed with various vasodilators.
avorable and sustained results were convincingly shown
nly by the use of high doses of calcium-channel blockers
CCBs), but only in the minority of patients who responded
o acute vasoreactivity testing. Also, oral anticoagulant
reatment was considered effective based on retrospective or
ncontrolled studies. Finally, in the 1990s, the complex
reatment with continuous intravenous (IV) administration
f epoprostenol was shown in three non-blinded RCTs to
onsistently improve symptoms and survival in the more
evere cases. In the same period, favorable results of different
From the *Institute of Cardiology, University of Bologna, Bologna, Italy; †De-
artment of Internal Medicine II, Justus-Liebig-University, Giessen, Germany;
Departement de Cardiologie et Laboratoire de Physiologie, Hoˆpital Erasme,
niversite´ Libre de Bruxelles, Brussels, Belgium; §Division of Pulmonary and Critical
are Medicine, University of Paris-Sud, Paris, France; and Division of Pulmonary
nd Critical Care Medicine, University of California, San Diego, California.
Manuscript received January 7, 2004; revised manuscript received February 9, 2004,nccepted February 23, 2004.ncontrolled series of PAH patients who underwent balloon
trial septostomy or lung transplantation were also reported.
Recently, three phase II studies and nine phase III RCTs
ith new compounds have been completed in PAH patients
nd six more are ongoing or planned. In addition, three
CTs testing the combination of new compounds with
poprostenol have been completed or planned. More than
,500 patients have been or will be involved in this unprec-
dented effort to find effective treatments and, ultimately, a
ure for PAH.
The impressive amount of knowledge derived from these
tudies can allow us, for the first time in the history of PAH
herapy, to shift from a clinical-based to an evidence-based
reatment strategy. The purpose of the present report is to
ompare the RCTs performed in PAH and to propose an
vidence-based grading system and a treatment algorithm
hat incorporate the currently available therapies.
NCONTROLLED CLINICAL STUDIES IN PAH
nticoagulants. The evidence for favorable effects of oral
nticoagulant treatment in patients with idiopathic pulmo-
ary arterial hypertension (IPAH) or PAH associated with
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Treatment Algorithm in Pulmonary Hypertension June 16, 2004:81S–88Snorexigens is based on retrospective analysis of single-
enter studies (1–3). The survival of anticoagulated patients,
elected on the basis of clinical judgment, was improved as
ompared to a concurrent population that was not treated
ith oral anticoagulants. Three-year survival improved from
1% to 49% in the series reported by Fuster et al. (1) and
rom 31% to 47% in the series of Rich et al. (2). The design
f these studies was not randomized, and one can argue that
he lower survival of the control groups could be related to
omorbidity that precluded the use of anticoagulation in the
ntreated patients. In addition, only IPAH and anorexigen-
elated PAH patients were included in the studies. In recent
CTs, oral anticoagulants were administered in 51% to 86%
f subjects at study entry. Interestingly, the highest preva-
ence of oral anticoagulant treatment was seen in the trials
nvolving mainly IPAH patients in New York Heart Asso-
iation (NYHA) functional class III and IV, whereas the
owest prevalence was observed in the trial of patients with
cleroderma. It should be emphasized that there is no
vidence of any difference in efficacy of oral anticoagulant
herapy based on functional class severity.
iuretics, digoxin, and oxygen. The clear symptomatic
nd clinical benefits of diuretic treatment in right heart
ailure preclude the need for controlled trials to show
fficacy in PAH. In the recent RCTs on new treatments,
9% to 70% of patients were treated with diuretics. How-
ver, the lack of trials with specific classes of diuretics in
AH and the individual variability in responses leave the
hoice of the type and the dose of drug to be used in
ndividual cases to the experience of the physician.
Short-term IV administration of digoxin in IPAH pro-
uces a modest increase in cardiac output and a significant
eduction in circulating norepinephrine; however, no data
re available on the effects of long-term treatment. Accord-
ngly, the use of digitalis in PAH patients is based primarily
n the judgment of the physician rather than on scientific
vidence of efficacy. Digoxin was administered to 18% to
3% of patients upon entering recent RCTs in PAH.
No consistent data are currently available on the effects of
ong-term oxygen treatment in PAH. Although improve-
ent in pulmonary hypertension with low-flow supplemen-
al oxygen has been reported in some PAH patients, this has
ot been confirmed in controlled trials. In a controlled study
Abbreviations and Acronyms
CCB  calcium channel blocker
ERA  endothelin-1 receptor antagonist
ETA  endothelin receptor A
IPAH  idiopathic pulmonary arterial hypertension
IV  intravenous
NYHA  New York Heart Association
PAH  pulmonary arterial hypertension
RCT  randomized controlled trialf Eisenmenger syndrome, nocturnal oxygen therapy had no cffect on hematologic variables, quality of life, or survival
4).
alcium channel blockers. Favorable clinical and prog-
ostic effects of high doses of calcium channel blocker
CCB) drugs in vasoreactive patients with IPAH have been
hown in single-center, nonrandomized, noncontrolled
tudies (2,5–8). In these studies, the control group consisted
f nonvasoreactive patients who may have a poorer progno-
is as compared to vasoreactive individuals (6). Conversely,
he demonstration of a consistent reduction of pulmonary
rtery pressure by acute pharmacological testing in vasore-
ctive patients raises ethical questions on the appropriate-
ess of performing a placebo-controlled clinical trial in these
atients.
According to the definition of “a positive acute vasoreac-
ive response” proposed in this Supplement (reduction of
ean pulmonary arterial pressure 10 mm Hg to reach a
ean pulmonary arterial pressure 40 mm Hg with a
ncrease or unchanged cardiac output with acute pulmonary
asodilator challenge), only about 10% to 15% of IPAH
atients will meet these criteria (8). In addition, only about
ne-half of these will manifest a sustained response to high
oses of CCB therapy as defined by a long-term hemody-
amic (assessed after at least three months) and functional
NYHA functional class I and II) improvement in the
bsence of additional treatments (8).
Favorable results of long-term administration of high
oses of CCBs have also been shown in children with
PAH (7). In contrast, the effects of high-dose CCBs on
ssociated forms of PAH have not yet been clearly demon-
trated (9).
alloon atrial septostomy. The role of balloon atrial
eptostomy in the treatment of PAH patients is uncertain
ecause its efficacy has been reported only in small series and
ase reports, totalling approximately 120 published cases
10,11). In most circumstances, this intervention has been
erformed in severely ill patients as a bridge to lung
ransplantation, which may explain a procedure mortality
ate ranging from 5% to 15%. In addition to symptomatic
nd hemodynamic improvement, an increase of survival as
ompared with historical control groups has also been
hown (12). At present, balloon atrial septostomy is indi-
ated for advanced NYHA functional class III and class IV
atients who are refractory to all available medical treat-
ents; septostomy is used either as a bridge to lung
ransplantation or as the sole treatment modality when
ther options are not available (11).
ung transplantation. As with many other surgical proce-
ures performed in severely ill patients, lung transplantation in
AH has been assessed only in prospective uncontrolled series,
ecause formal RCTs are considered unethical in the absence
f alternative treatment options (11). The three- and five-year
urvival after lung transplantation is approximately 55% and
5%, respectively (13). Accordingly, lung transplantation is
ndicated in PAH patients with advanced NYHA functional
lass III and IV symptoms that are refractory to available
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June 16, 2004:81S–88S Treatment Algorithm in Pulmonary Hypertensionedical treatments. The unpredictability of the length of time
n the waiting list and of donor organ shortage complicate the
ecision making regarding the appropriate timing of listing for
ransplantation.
ONTROLLED CLINICAL TRIALS IN PAH
ynthetic prostacyclin and prostacyclin analogues. The
fficacy of continuous IV administration of epoprostenol
synthetic prostacyclin, Flolan) has been tested in three
nblinded, controlled clinical trials in IPAH (14,15) and in
AH associated with the scleroderma spectrum of diseases
16), and the results are summarized in Table 1. Epopro-
tenol improves symptoms, exercise capacity, and hemody-
amics in both clinical conditions, and it is the only
reatment to be shown in RCTs to improve patient survival
n IPAH.
Four RCTs have been performed with prostacyclin ana-
ogues and results are summarized in Table 2.
The effects of continuous subcutaneous administration of
reprostinil in PAH were studied in the largest worldwide
CT performed in this condition, and improvements in
xercise capacity, hemodynamics, and clinical events were
hown (Table 2) (17). One additional pilot controlled study
as performed with treprostinil in 26 PAH patients and
howed trends in the improvement of 6-min walk distance
nd in the reduction of pulmonary vascular resistance (18).
The orally active prostacyclin analogue beraprost has been
valuated in PAH patients in two RCTs in Europe (19) and
Table 1. Controlled Clinical Trials With Epop
Hypertension
Trial
Epoprostenol IPA
(Ref. 14)
Patients (n) 23
Trial type Controlled
Drug/route Epoprostenol/IV
Duration (months) 2
Primary end points Hemodynamics
NYHA functional class (%)*
II 9
III 65
IV 26
Etiology (%)
IPAH 100
CTD —
CHD —
HIV —
Treatment effect
Peak VO2 (% predicted) N/A
6-min walk change (m) 45
Hemodynamics Improved
Clinical events Reduced
*Sum of percentage may not be 100% for rounding to the n
CHD  congenital heart disease (congenital systemic-to
idiopathic pulmonary aterial hypertension; IV  intravenousn the U.S., respectively (20) (Table 2). In the first study, an bncrease in exercise capacity was seen in IPAH subjects after
hree months. In the second randomized trial that lasted 12
onths, improvement in exercise capacity was observed at
ix months but not thereafter. No hemodynamic improve-
ents were observed in the long-term study, and clinical
vents were reduced only at the six-month evaluation.
Inhaled iloprost has been evaluated in one RCT that
nrolled both patients with PAH and chronic thromboem-
olic pulmonary hypertension (21) (Table 2). The study
howed an increase in exercise capacity and improvement in
ymptoms, pulmonary vascular resistance, and clinical
vents in IPAH patients only. Continuous IV administra-
ion of iloprost has been shown to be effective in a small
eries of patients with PAH and chronic thromboembolic
ulmonary hypertension (22).
ndothelin-1 receptor antagonists. Three RCTs with
ndothelin-1 receptor antagonists (ERAs) have been per-
ormed in PAH patients (Table 3). The orally active, dual
RA bosentan has been evaluated in PAH patients in two
CTs that have shown improvement in exercise capacity,
unctional class, hemodyamics, echocardiographic and
oppler variables, and time to clinical worsening (23–25).
Sitaxsentan, a selective orally active endothelin A receptor
ETA) antagonist has been assessed in PAH patients in one
CT that demonstrated improvement in exercise capacity,
emodynamics, and clinical events (only for the lower dose
ested) (26,27). An additional pilot study with this com-
ound in 20 PAH patients has shown similar results (28).
Ambrisentan, a selective, orally active ETA receptor
ntagonist, has thus far been evaluated only in a pilot
nol in Patients With Pulmonary Arterial
Epoprostenol IPAH
(Ref. 15)
Epoprostenol
Scleroderma
(Ref. 16)
81 111
Controlled Controlled
Epoprostenol/IV Epoprostenol/IV
3 3
Hemodynamics 6-min walk
— 5
75 78
25 17
100 —
— 100
— —
— —
N/A N/A
47 94
Improved Improved
Reduced (improved survival) No change
unit; 0.5 is rounded to the upper unit.
onary shunts); CTD  connective tissue disease; IPAH 
 not available; NYHA  New York Heart Association.roste
H
earest
-pulmlinded, dose-comparison study in 64 PAH patients. Pre-
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Treatment Algorithm in Pulmonary Hypertension June 16, 2004:81S–88Siminary results show improvements in exercise capacity and
emodynamics that appear similar to the results observed
ith other ERAs (29).
Additional phase III RCTs with sitaxsentan and am-
Table 3. Controlled Clinical Trials With Endo
Pulmonary Arterial Hypertension
Trial
Bosentan P
(Ref. 21
Patients (n) 32
Trial type Controlle
Drug Bosentan
Duration (months) 3
Primary end points 6-min wa
NYHA functional class (%)
II —
III 100
IV —
Etiology (%)*
PPH 85
CTD 15
CHD —
HIV —
Treatment effect
Peak VO2 (% predicted) N/A
6-min walk change (m) 76
Hemodynamics Improve
Clinical events Reduced
*Sum of percentages may not be 100% for rounding to the nea
‡Only for 100-mg dose.
BREATHE-1  Bosentan Randomized trial of Endoth
congenital heart disease (congenital systemic-to-pulmonary
able 2. Controlled Clinical Trials With New Prostacyclin Analo
Trial
Treprostinil
(Ref. 17)
ALP
(R
atients (n) 469
rial type Controlled Co
rug/route Treprostinil/sc Ber
uration (months) 3
rimary end points 6-min walk 6-m
YHA functional class (%)
II 11
III 82
IV 7
tiology (%)†
IPAH 58
CTD 19
CHD 24
CTEPH —
HIV —
P-PH —
reatment effect
eak VO2 (% predicted) N/A
-min walk change (m) 16‡
emodynamics Improved No
linical events Reduced No
Combined end point of an improvement in NYHA functional class and a 10% imp
nit; 0.5 is rounded to the upper unit. ‡Median change. §Statistically significant at six
onsistent improvement of other parameters is observed in postinhalation period.
AIR  Aerosolised Iloprost Randomized Study; ALPHABET  Arterial Pulm
congenital systemic-to-pulmonary shunts); CTD  connective tissue disease; CTE
rterial hypertension; inh  inhaled; N/A  not available; NYHA  New York Hpulmonary arterial hypertension; N/A  not available; STRIDE-1risentan are ongoing or are planned; these trials will further
xplore both the efficacy and side effects profile of selective
TA receptor antagonists and allow comparisons with
osentan.
n-1 Receptor Antagonists in Patients With
BREATHE-1
(Ref. 24)
STRIDE-1
(Ref. 27)
213 178
Controlled Controlled
Bosentan Sitaxsentan
4 3
6-min walk Peak VO2
— 33
91 66
9 1
70 53
30 24
— 24
— —
N/A 3%†
44 34
N/A Improved
Reduced Reduced‡
it; 0.5 is rounded to the upper unit. †Only for 300-mg dose.
ntagonist Therapy for pulmonary hypertension; CHD 
s); CTD  connective tissue disease; IPAH  idiopathic
in Patients With Pulmonary Arterial Hypertension
ET
9)
Beraprost—
Long Term
(Ref. 20)
AIR
(Ref. 21)
116 203
ed Controlled Controlled
t/os Beraprost/os Iloprost/inh
12 3
alk Disease progression 6-min walk† NYHA*
53 —
47 59
— 41
74 54
10 17
16 —
— 28
— —
— —
Trend to increase N/A
31‡§ 36
ge No change Improved
ge Reduced§ Reduced
ent in 6-min walk. †Sum of percentage may not be 100% for rounding to the nearest
s. Only pulmonary vascular resistance improved in preinhalation period, and a more
Hypertension And Beraprost European Trial; CHD  congenital heart disease
chronic thromboembolic pulmonary hypertension; IPAH  idiopathic pulmonary
ssociation; os  oral; P-PH  porto-pulmonary hypertension; sc  subcutaneous.theli
ilot
)
d
lk
d
rest un
elin A
shuntgues
HAB
ef. 1
130
ntroll
apros
3
in w
49
51
—
48
7
21
—
7
16
N/A
25
chan
chan
rovem
month
onary
PH  Sitaxsentan to Relieve Impaired Exercise study.
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June 16, 2004:81S–88S Treatment Algorithm in Pulmonary Hypertensionhosphodiesterase-V inhibitors. A number of uncon-
rolled studies have reported favorable effects of the orally
ctive phosphodiesterase-V inhibitor sildenafil in PAH
30–32). A RCT with a cross-over design has been recently
ublished: sildenafil 25 to 100 mg tid administered in 22
YHA functional class II and III PAH patients has
mproved after six weeks’ symptoms, the exercise capacity as
ssessed by the Naughton protocol on the treadmill, and the
emodynamics (33). Results of a pivotal RCT on approxi-
ately 300 PAH patients are expected in the second quarter
f 2004; the findings of this major trial will define the
recise role of sildenafil in the treatment algorithm of PAH.
ombination therapy. Combination treatment is an attrac-
ive option to address the multiple pathophysiologic mecha-
isms that are present in PAH. Both the efficacy and the safety
f the combination of bosentan and epoprostenol were inves-
igated in a study of 33 patients with severe PAH enrolled in
placebo-controlled, prospective study (BREATHE-2). Im-
roved hemodynamics, exercise capacity, and functional class
ere observed in both groups. A preliminary report shows that
here was a trend for a greater (though nonsignificant) im-
rovement in all hemodynamic parameters in the combination
reatment group (34). Additional RCTs that are ongoing or
lanned will explore the effects of combinations using epoproste-
ol with sildenafil, sitaxsentan, and ambrisentan, respectively.
In patients with PAH who are deteriorating despite
hronic treatment with nonparenteral prostanoids, addition
f bosentan (35) or sildenafil (36) to the ongoing treatment
esulted in favorable improvements of pulmonary hemody-
amics and exercise capacity in uncontrolled studies.
eneral comments on controlled clinical trials. The
CTs in PAH have produced a tremendous increase of
oth knowledge and therapeutic options in PAH. Although
hese studies have similar designs, treatment duration, and
nd points, close analyses of baseline NYHA functional
lass and etiology profiles (Tables 1 to 3) show substantial
ifferences. Accordingly, comparisons may be misleading;
mprovement, albeit to different degrees, of the mean
xercise capacity as assessed by the 6-min walk distance has
een observed in all these studies. Peak VO2 was assessed
nly in two trials, and the results were not completely
onsistent with changes in the 6-min walk distance. In
valuation of the clinical relevance of exercise capacity
mprovements, additional elements should be considered
uch as baseline functional class, effects on combined clinical
vents (i.e., hospitalizations, mortality, rescue therapies),
nd hemodynamic effects (Tables 1 to 3). As mentioned
reviously, a survival benefit has been demonstrated in only
ne controlled, unblinded study using epoprostenol in
atients with severe IPAH. Because epoprostenol is consid-
red rescue therapy based on these results, the more recent
CTs could not be ethically performed to assess mortality
s an end point. Furthermore, severely ill subjects requiring
poprostenol treatment were excluded in the recent RCTs,
esulting in an overall low mortality of these study
opulations. cEVEL OF EVIDENCE FOR EFFICACY
arious grading systems for the definition of the level of
vidence of treatments have been proposed. Table 4 shows
he grading system adopted in the current review, which is
ased on the number of favorable RCTs performed with a
iven compound. The analysis takes into consideration the
tudies reported and the RCTs presented in Tables 1 to 3.
he grading system was adapted from the European Society
f Cardiology recommendation for guidelines (37). The
nly difference is that we did not include in category B
nonrandomized studies” because all these studies in PAH
re rather small; therefore, they are included in category C
Table 4). In category B, we included the wording “multiple
andomized clinical trials with heterogeneous results” be-
ause this situation may happen (and has happened) and
his definition is more comprehensive even if the outcome is
hat “a single randomized clinical trial” resulted positive.
This approach may present some limitations that should
e taken into account:
. The level of evidence may change over time as a result of
additional studies performed.
. The grading system does not address the sample sizes of
the RCTs.
able 4. Grading of Evidence for Efficacy
evel of Evidence A Data derived from multiple randomized clinical
trials or meta-analyses.
evel of Evidence B Data derived from a single randomized clinical
trial or from multiple randomized clinical
trials with heterogeneous results.
evel of Evidence C Data derived from small nonrandomized studies
and/or consensus opinion of experts.
able 5. Grading of Evidence for Efficacy and Regulatory
pproval Status of Selected Treatments
Treatment
No. of
RCTs*
Grading of
Evidence
Regulatory
Approval
ral anticoagulants 3† C —
iuretics — C —
igoxin — C —
xygen — C —
alcium channel blockers 5† C —
poprostenol 3 A Europe, U.S.,
Canada
reprostinil 2 B U.S.
loprost (inhalation) 1 B Europe,
Australia
loprost (IV) 1† C New Zealand
eraprost 2 B Japan
osentan 2 A Europe, U.S.,
Canada
itaxsentan 1 B —
mbrisentan 1† C —
ildenafil 1 B —
AS Multiple† C —
ung transplantation Multiple† C —
See appropriate paragraph of the text for references. †Uncontrolled and/or retro-
pective study.
BAS  balloon atrial septostomy; IV  intravenous; RCT  randomized
ontrolled trials.
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Treatment Algorithm in Pulmonary Hypertension June 16, 2004:81S–88S. The level of evidence for efficacy should not be confused with
the strength of clinical efficacy, which depends on the
pharmacodynamic effects of the compound and on patient
response. For example, a compound that increased the
6-min walking distance in two controlled clinical trials by
40 m will be rated with a Level of Evidence A (Table 4). If
a more potent compound increased the 6-min walking
distance by 80 m in only one controlled clinical trial it will
be rated Level of Evidence B even though the clinical
relevance of the effect is greater.
. Regulatory agencies may grant approval to a given treatment
on the basis of a single RCT with an appropriate sample size
and prespecified adequate statistical requirements.
Table 5 shows the grading of evidence for efficacy and
egulatory approval status of selected treatments.
VIDENCE-BASED TREATMENT ALGORITHM
treatment algorithm based on the evidence derived by
linical trials is depicted in Figure 1. The algorithm is
estricted to patients in NYHA functional class III or IV
igure 1. Evidence-based treatment algorithm. Levels of evidence A, B, and C
1) The algorithm is restricted to patients in New York Heart Association (NYH
n controlled clinical trials. For NYHA functional class I or II, very few data
poradic idiopathic pulmonary arterial hypertension (IPAH) patients, and in p
se. Extrapolation of these recommendations to the other PAH subgroups sh
asoreactivity tests, and to the treatment options available, it is strongly recomm
enter. (3) The acute vasoreactivity test should be performed in all patients wi
ith IPAH and PAH associated to anorexigen use. (4) A positive acute respon
0 mm Hg to40 mm Hg, with an increase or unchanged cardiac output durin
5) Sustained response to calcium channel blockers (CCBs) is defined as patie
everal months of treatment. (6) In patients in NYHA functional class III
poprostenol, or prostanoid analogues. Phosphodiesterase-V (PDE5) inhibito
herapies. (7) Most experts consider that NYHA functional class IV patients in
orldwide experience, and rapidity of action).ecause such patients represent the predominant populationncluded in RCTs. For NYHA functional class I or II, very
ew data are available, and the most appropriate strategy has
till to be determined and possibly validated by specific
tudies. In addition, the different treatments have been
valuated mainly in sporadic IPAH, and in PAH associated
ith scleroderma or to anorexigen use. Extrapolation of
hese recommendations to the other PAH subgroups should
e done with caution.
The suggested initial approach, after the diagnosis of PAH,
s to treat patients with oral anticoagulant drugs (if no contra-
ndication exists), diuretics (in cases of fluid retention), and
upplemental oxygen (in cases of hypoxemia) even though
CTs with these compounds are lacking. The patient should
hen be referred to a center experienced with vasoreactivity
esting and the treatment of pulmonary vascular diseases.
cute vasoreactivity testing should be performed in all patients
ith PAH, although patients with IPAH and PAH associated
ith anorexigen use are the most likely to exhibit a positive
esponse. Vasoreactive patients, as defined above, should be
reated with optimally tolerated doses of CCB; maintenance of
he response (defined as NYHA functional class I or II with
ing according to Tables 4 and 5; inh inhaled; iv continuous intravenous.
unctional class III or IV because they represent the largest population included
vailable. In addition, the different treatments have been evaluated mainly in
ary arterial hypertension (PAH) associated with scleroderma or to anorexigen
be done with caution. (2) Owing to the complexity and dangers of the acute
d that consideration be given to referral of patients with PAH to a specialized
H even if the greater incidence of positive response is achieved in individuals
vasodilators is defined as a drop in mean pulmonary artery pressure of at least
te challenge with inhaled nitric oxide (NO), IV epoprostenol, or IV adenosine.
ing in NYHA functional class I or II with near-normal hemodynamics after
line therapy may include oral endothelin receptor antagonists, chronic IV
uld be considered in patients who have failed or are not candidates to other
able condition should be treated with IV epoprostenol (survival improvement,grad
A) f
are a
ulmon
ould
ende
th PA
se to
g acu
nts be
, first-
rs sho
unst
n
t
t
c
e
c
a
m
i
r
a
f
o
i
e
a
p
c
c
w
R
E
p
d
t
c
a
a
b
p
i
c
w
o
a
l
i
p
m
s
R
I
4
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
87SJACC Vol. 43, No. 12 Suppl S Galie` et al.
June 16, 2004:81S–88S Treatment Algorithm in Pulmonary Hypertensionear-normal hemodynamics) should be confirmed after three
o six months of treatment. Nonresponders to acute vasoreac-
ivity testing, or responders who remain in NYHA functional
lass III, should be considered candidates for treatment with
ither an ERA or a prostanoid. At present, the only commer-
ially available and approved ERA is the oral active dual-
ntagonist bosentan. Among prostanoids, treprostinil is ad-
inistered subcutaneously and has been approved in the U.S.;
loprost, administered by aerosol, has been approved in Eu-
ope, whereas beraprost is approved in Japan. Continuous IV
dministration of epoprostenol may also be used in NYHA
unctional class III patients who are refractory to ERAs or
ther prostanoids.
The choice of drug is dependent on a variety of factors,
ncluding the approval status, route of administration, side-
ffect profile, and the physician’s experience. The orally
ctive phosphodiesterase-V inhibitor sildenafil is not ap-
roved for the treatment of PAH, and its use should be
onsidered in patients with PAH, who have failed or are not
andidates for other available therapy. The role of this drug
ill be better defined after the evaluation of the pivotal
CT that is currently ongoing.
Continuous IV epoprostenol, approved in the U.S. and
urope, may be considered as first-line therapy for IPAH
atients in NYHA functional class IV because of the
emonstrated survival benefit in this subset.
Although both bosentan and treprostinil are approved for
his population, only a small number of NYHA functional
lass IV patients were included in the clinical trials of these
gents. Accordingly, most experts consider these treatments as
second line for severely ill patients. Although no RCTs have
een performed with the continuous IV delivery of iloprost this
rostacyclin analogue, administered intravenously is approved
n New Zealand for PAH patients.
Combination therapy (e.g., ERA  prostanoids) may be
onsidered for patients who fail to show improvement or
ho deteriorate with first-line treatment, even though data
n this specific strategy are limited and largely uncontrolled
t this point. Appropriate protocols for timing and dosing to
imit possible side effects of the combination have still to be
mplemented.
Finally, both balloon atrial septostomy and lung trans-
lantation are indicated for refractory PAH or where
edical treatments are unavailable. These procedures
hould be performed only in experienced centers.
eprint requests and correspondence: Dr. Nazzareno Galie`,
stituto di Cardiologia, Universita` di Bologna, via Massarenti, 9,
0138-Bologna, Italy. E-mail: n.galie@bo.nettuno.it.
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